MX2010003765A - Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6. - Google Patents
Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6.Info
- Publication number
- MX2010003765A MX2010003765A MX2010003765A MX2010003765A MX2010003765A MX 2010003765 A MX2010003765 A MX 2010003765A MX 2010003765 A MX2010003765 A MX 2010003765A MX 2010003765 A MX2010003765 A MX 2010003765A MX 2010003765 A MX2010003765 A MX 2010003765A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- pharmaceutically acceptable
- disorders
- stereoisomers
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Abstract
La presente invenci?n se relaciona con compuestos novedosos de aminoarilsulfonamida de la f?rmula (I), sus derivados, sus estereois?meros, sus sales farmac?uticamente aceptables y las composiciones farmac?uticamente aceptables que los contienen. La presente invenci?n tambi?n se relaciona con un proceso para la preparaci?n de los compuestos novedosos anteriores, sus derivados, sus estereois?meros, sus sales farmac?uticamente aceptables y las composiciones farmac?uticamente aceptables que los contienen. Los compuestos de la invenci?n son ?tiles en el tratamiento de varios trastornos que est?n relacionados con las funciones del receptor de 5-HT6. De manera espec?fica, los compuestos de esta invenci?n tambi?n son ?tiles en el tratamiento de varios trastornos del CNS, trastornos hematol?gicos, trastornos de la alimentaci?n, obesidad, ansiedad, depresi?n, enfermedades asociadas con el dolor, enfermedades respiratorias, enfermedades gastrointestinales, cardiovasculares y c?ncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2433CH2007 | 2007-10-26 | ||
| PCT/IN2008/000281 WO2009053997A1 (en) | 2007-10-26 | 2008-05-02 | Amino arylsulfonamide compounds and their use as 5-ht6 ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010003765A true MX2010003765A (es) | 2010-04-30 |
Family
ID=39769531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010003765A MX2010003765A (es) | 2007-10-26 | 2008-05-02 | Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7964627B2 (es) |
| EP (1) | EP2200980B9 (es) |
| JP (1) | JP5236001B2 (es) |
| KR (1) | KR101268654B1 (es) |
| CN (1) | CN101835748B (es) |
| AT (1) | ATE518833T1 (es) |
| AU (1) | AU2008315309B2 (es) |
| BR (1) | BRPI0816571A2 (es) |
| CA (1) | CA2703157C (es) |
| CY (1) | CY1112181T1 (es) |
| DK (1) | DK2200980T3 (es) |
| EA (1) | EA017154B1 (es) |
| ES (1) | ES2370680T3 (es) |
| HK (1) | HK1147750A1 (es) |
| HR (1) | HRP20110780T2 (es) |
| IL (1) | IL205231A (es) |
| MX (1) | MX2010003765A (es) |
| NZ (1) | NZ585374A (es) |
| SI (1) | SI2200980T1 (es) |
| WO (1) | WO2009053997A1 (es) |
| ZA (1) | ZA201002165B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102153884B (zh) * | 2011-02-16 | 2013-06-19 | 连云港清泰化工有限公司 | 一种墨水型染料及其制备方法与用途 |
| EP2763676B1 (en) | 2011-10-03 | 2019-12-25 | The University of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| US20130202581A1 (en) * | 2012-02-02 | 2013-08-08 | Curelon Llc | Enzyme compositions and use thereof for wound healing |
| WO2015090233A1 (en) | 2013-12-20 | 2015-06-25 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| HUE044011T2 (hu) * | 2014-08-16 | 2019-09-30 | Suven Life Sciences Ltd | 1-[(2-bromofenil) szulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)metil]-1H-indol dimezilát monohidrát aktív metabolitja és az aktív metabolit dimezilát dihidrát sója |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| ES2244082T3 (es) | 1997-07-11 | 2005-12-01 | Smithkline Beecham Plc | Derivados de sulfonamida que son antagonistas del receptor 5-ht6 y procedimiento para su preparacion. |
| ES2193607T3 (es) * | 1998-01-16 | 2003-11-01 | Hoffmann La Roche | Derivados de benzosulfona . |
| GB9801392D0 (en) | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
| GB9803411D0 (en) | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| DE69937372T2 (de) | 1999-04-21 | 2008-06-26 | Nps Allelix Corp., Mississauga | Piperidin-indol derivate mit 5-ht6 affinität |
| GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| EP1377580B1 (en) | 2001-01-30 | 2006-09-27 | Eli Lilly And Company | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor |
| AU2002313673B2 (en) | 2001-02-08 | 2006-09-07 | Memory Pharmaceuticals Corporation | Trifluoromethylpurines as phosphodiesterase 4 inhibitors |
| BR0210929A (pt) | 2001-06-07 | 2004-06-08 | Hoffmann La Roche | Derivados de indol com afinidade para o receptor 5-ht6 |
| US20050255529A1 (en) | 2002-02-01 | 2005-11-17 | Stefan Golz | Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| JP2005522432A (ja) | 2002-02-05 | 2005-07-28 | グラクソ グループ リミテッド | ニューロン成長の促進方法 |
| AR039127A1 (es) | 2002-03-27 | 2005-02-09 | Glaxo Group Ltd | Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento |
| WO2004035047A1 (en) * | 2002-10-18 | 2004-04-29 | F. Hoffmann-La Roche Ag | 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity |
| AU2003292508A1 (en) * | 2002-11-28 | 2004-06-18 | Suven Life Sciences Limited | N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands |
| ES2310243T3 (es) | 2002-11-28 | 2009-01-01 | Suven Life Sciences Limited | Indoles n-aril-3-sulfonil sustituidos que tienen afinidad por receptores de serotonina, proceso para su preparacion y composicion farmaceutica que los contiene. |
| NZ540842A (en) * | 2002-11-28 | 2008-05-30 | Suven Life Sciences Ltd | N-arylsulfonyl-3-aminoalkoxyindoles |
| DK1581538T3 (da) | 2002-12-18 | 2007-06-25 | Suven Life Sciences Ltd | Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet |
| CN101258144B (zh) * | 2005-08-12 | 2012-05-30 | 苏文生命科学有限公司 | 作为功能性5-ht6配体的氨基芳基磺酰胺衍生物 |
-
2008
- 2008-05-02 WO PCT/IN2008/000281 patent/WO2009053997A1/en active Application Filing
- 2008-05-02 JP JP2010530633A patent/JP5236001B2/ja active Active
- 2008-05-02 NZ NZ585374A patent/NZ585374A/en not_active IP Right Cessation
- 2008-05-02 DK DK08776656.4T patent/DK2200980T3/da active
- 2008-05-02 ES ES08776656T patent/ES2370680T3/es active Active
- 2008-05-02 US US12/682,596 patent/US7964627B2/en not_active Expired - Fee Related
- 2008-05-02 SI SI200830420T patent/SI2200980T1/sl unknown
- 2008-05-02 CN CN2008801127356A patent/CN101835748B/zh not_active Expired - Fee Related
- 2008-05-02 KR KR1020107010395A patent/KR101268654B1/ko active IP Right Grant
- 2008-05-02 AT AT08776656T patent/ATE518833T1/de active
- 2008-05-02 BR BRPI0816571A patent/BRPI0816571A2/pt active Search and Examination
- 2008-05-02 CA CA2703157A patent/CA2703157C/en not_active Expired - Fee Related
- 2008-05-02 MX MX2010003765A patent/MX2010003765A/es active IP Right Grant
- 2008-05-02 EA EA201070527A patent/EA017154B1/ru not_active IP Right Cessation
- 2008-05-02 EP EP08776656A patent/EP2200980B9/en active Active
- 2008-05-02 AU AU2008315309A patent/AU2008315309B2/en not_active Ceased
-
2010
- 2010-03-26 ZA ZA2010/02165A patent/ZA201002165B/en unknown
- 2010-04-21 IL IL205231A patent/IL205231A/en active IP Right Grant
-
2011
- 2011-02-25 HK HK11101861.1A patent/HK1147750A1/xx not_active IP Right Cessation
- 2011-10-26 HR HRP20110780TT patent/HRP20110780T2/hr unknown
- 2011-11-03 CY CY20111101058T patent/CY1112181T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20110780T1 (en) | 2011-11-30 |
| HK1147750A1 (en) | 2011-08-19 |
| ATE518833T1 (de) | 2011-08-15 |
| DK2200980T3 (da) | 2011-11-21 |
| ZA201002165B (en) | 2011-05-25 |
| EA201070527A1 (ru) | 2010-10-29 |
| ES2370680T3 (es) | 2011-12-21 |
| JP5236001B2 (ja) | 2013-07-17 |
| NZ585374A (en) | 2011-09-30 |
| EP2200980B9 (en) | 2011-12-28 |
| CN101835748A (zh) | 2010-09-15 |
| CY1112181T1 (el) | 2015-12-09 |
| EA017154B1 (ru) | 2012-10-30 |
| CN101835748B (zh) | 2012-11-14 |
| EP2200980B1 (en) | 2011-08-03 |
| BRPI0816571A2 (pt) | 2015-12-22 |
| WO2009053997A1 (en) | 2009-04-30 |
| HRP20110780T2 (hr) | 2018-06-29 |
| EP2200980A1 (en) | 2010-06-30 |
| US20100216861A1 (en) | 2010-08-26 |
| US7964627B2 (en) | 2011-06-21 |
| SI2200980T1 (sl) | 2011-12-30 |
| KR101268654B1 (ko) | 2013-05-29 |
| KR20100069707A (ko) | 2010-06-24 |
| AU2008315309B2 (en) | 2011-06-09 |
| CA2703157A1 (en) | 2009-04-30 |
| JP2011500792A (ja) | 2011-01-06 |
| CA2703157C (en) | 2013-02-05 |
| IL205231A0 (en) | 2010-12-30 |
| AU2008315309A1 (en) | 2009-04-30 |
| IL205231A (en) | 2014-03-31 |
| ES2370680T9 (es) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY179527A (en) | Catecholamine derivatives useful for the treatment of parkinson's disease | |
| UA98961C2 (uk) | Похідні піразинону та їх застосування у лікуванні легеневих захворювань | |
| JO2686B1 (en) | Vehicles | |
| TW200640863A (en) | Compounds which potentiate glutamate receptor and uses thereof in medicine | |
| WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| HRP20110780T1 (en) | Amino arylsulfonamide compounds and their use as 5-ht6 ligands field of invention | |
| TW200604182A (en) | Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments | |
| HK1138264A1 (en) | Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands | |
| MX2009006077A (es) | Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6. | |
| TW200728281A (en) | Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions | |
| MX2009006757A (es) | Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6. | |
| WO2009027736A3 (en) | 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer | |
| MX2013001988A (es) | Compuestos de heterociclilo comoligandos del receptor h3 de la histamina | |
| MX2011008857A (es) | Derivados de oxiindol con actividad agonistica del receptor de motilina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |